484 related articles for article (PubMed ID: 26279026)
41. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer.
Shioyama Y; Tokuuye K; Okumura T; Kagei K; Sugahara S; Ohara K; Akine Y; Ishikawa S; Satoh H; Sekizawa K
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):7-13. PubMed ID: 12694818
[TBL] [Abstract][Full Text] [Related]
42. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume.
Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F
Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555
[TBL] [Abstract][Full Text] [Related]
43. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
Kim YS; Yoon SM; Choi EK; Yi BY; Kim JH; Ahn SD; Lee SW; Shin SS; Lee JS; Suh C; Kim SW; Kim DS; Kim WS; Park HJ; Park CI
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):76-81. PubMed ID: 15850905
[TBL] [Abstract][Full Text] [Related]
45. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
46. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.
Center B; Petty WJ; Ayala D; Hinson WH; Lovato J; Capellari J; Oaks T; Miller AA; Blackstock AW
J Thorac Oncol; 2010 Jan; 5(1):69-74. PubMed ID: 20035186
[TBL] [Abstract][Full Text] [Related]
47. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
[TBL] [Abstract][Full Text] [Related]
48. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
Ajlouni M; Chapman R; Kim JH
Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
[TBL] [Abstract][Full Text] [Related]
49. Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial.
Wu KL; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Zhao S
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1345-50. PubMed ID: 14630272
[TBL] [Abstract][Full Text] [Related]
50. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial.
Hayman JA; Martel MK; Ten Haken RK; Normolle DP; Todd RF; Littles JF; Sullivan MA; Possert PW; Turrisi AT; Lichter AS
J Clin Oncol; 2001 Jan; 19(1):127-36. PubMed ID: 11134205
[TBL] [Abstract][Full Text] [Related]
51. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.
Gomez DR; Gillin M; Liao Z; Wei C; Lin SH; Swanick C; Alvarado T; Komaki R; Cox JD; Chang JY
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):665-70. PubMed ID: 23688815
[TBL] [Abstract][Full Text] [Related]
52. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy.
Belderbos JS; De Jaeger K; Heemsbergen WD; Seppenwoolde Y; Baas P; Boersma LJ; Lebesque JV
Radiother Oncol; 2003 Feb; 66(2):119-26. PubMed ID: 12648783
[TBL] [Abstract][Full Text] [Related]
53. [Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
Zhu XZ; Wang LH; Ou GF; Zhou ZM; Chen DF; Xiao ZF; Feng QF; Zhang HX; Wang M; Yin WB
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):748-53. PubMed ID: 18396686
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer.
Nakajima K; Iwata H; Ogino H; Hattori Y; Hashimoto S; Toshito T; Hayashi K; Akita K; Baba F; Nakamae K; Mizoe JE; Shibamoto Y
Radiat Oncol; 2018 Oct; 13(1):199. PubMed ID: 30305125
[TBL] [Abstract][Full Text] [Related]
55. Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer.
Iwata H; Demizu Y; Fujii O; Terashima K; Mima M; Niwa Y; Hashimoto N; Akagi T; Sasaki R; Hishikawa Y; Abe M; Shibamoto Y; Murakami M; Fuwa N
J Thorac Oncol; 2013 Jun; 8(6):726-35. PubMed ID: 23459403
[TBL] [Abstract][Full Text] [Related]
56. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Campeau MP; Herschtal A; Wheeler G; Mac Manus M; Wirth A; Michael M; Hogg A; Drummond E; Ball D
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1371-5. PubMed ID: 19250769
[TBL] [Abstract][Full Text] [Related]
57. [Late course three-dimensional conformal radiotherapy in patients with stage III non-small cell lung cancer].
Wang XC; Wang SY; Yang S; Ding Y; Shang Y
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):726-8. PubMed ID: 15958322
[TBL] [Abstract][Full Text] [Related]
58. Patient outcomes of monotherapy with hypofractionated three-dimensional conformal radiation therapy for stage T2 or T3 non-small cell lung cancer: a retrospective study.
Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Fukushima S; Abe O; Saito T
Radiat Oncol; 2016 Jan; 11():3. PubMed ID: 26781290
[TBL] [Abstract][Full Text] [Related]
59. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Wu TC; Luterstein E; Neilsen BK; Goldman JW; Garon EB; Lee JM; Felix C; Cao M; Tenn SE; Low DA; Kupelian PA; Steinberg ML; Lee P
JAMA Oncol; 2024 Mar; 10(3):352-359. PubMed ID: 38206614
[TBL] [Abstract][Full Text] [Related]
60. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
